The stock of Biomarin Pharmaceutical Inc. (BMRN) has seen a -14.93% decrease in the past week, with a -19.56% drop in the past month, and a -14.09% decrease in the past quarter. The volatility ratio for the week is 1.67%, and the volatility levels for the past 30 days are at 2.46% for BMRN. The simple moving average for the last 20 days is -19.21% for BMRN stock, with a simple moving average of -17.83% for the last 200 days.
Is It Worth Investing in Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Right Now?
The price-to-earnings ratio for Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) is above average at 54.16x. The 36-month beta value for BMRN is also noteworthy at 0.33. There are mixed opinions on the stock, with 12 analysts rating it as a “buy,” 7 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BMRN is 187.99M, and at present, short sellers hold a 3.11% of that float. The average trading volume of BMRN on September 16, 2024 was 2.06M shares.
BMRN) stock’s latest price update
The stock price of Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has plunged by -15.50 when compared to previous closing price of 84.90, but the company has seen a -14.93% decline in its stock price over the last five trading sessions. zacks.com reported 2024-09-13 that The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Bernstein repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Bernstein is $110 based on the research report published on August 20, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see BMRN reach a price target of $72, previously predicting the price at $104. The rating they have provided for BMRN stocks is “Neutral” according to the report published on May 17th, 2024.
Evercore ISI gave a rating of “Outperform” to BMRN, setting the target price at $113 in the report published on May 14th of the current year.
BMRN Trading at -17.20% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.94% of loss for the given period.
Volatility was left at 2.46%, however, over the last 30 days, the volatility rate increased by 1.67%, as shares sank -19.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.04% lower at present.
During the last 5 trading sessions, BMRN fell by -14.08%, which changed the moving average for the period of 200-days by -17.43% in comparison to the 20-day moving average, which settled at $87.95. In addition, Biomarin Pharmaceutical Inc. saw -25.60% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Burkhart Erin, who sale 714 shares at the price of $90.00 back on Aug 13 ’24. After this action, Burkhart Erin now owns 14,449 shares of Biomarin Pharmaceutical Inc., valued at $64,260 using the latest closing price.
Burkhart Erin, the Officer of Biomarin Pharmaceutical Inc., proposed sale 714 shares at $90.00 during a trade that took place back on Aug 13 ’24, which means that Burkhart Erin is holding shares at $64,260 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.78 for the gross margin
The net margin for Biomarin Pharmaceutical Inc. stands at 0.1. The total capital return value is set at 0.04. Equity return is now at value 5.10, with 3.76 for asset returns.
Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 13.08.
Currently, EBITDA for the company is 261.98 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 5.27. The receivables turnover for the company is 3.75for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.05.
Conclusion
In summary, Biomarin Pharmaceutical Inc. (BMRN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
